/TYRA
Tyra Biosciences, Inc.
TYRA • NASDAQTYRA • NASDAQ • Healthcare
$39.61+3.47%+1.33
$39.61+3.47%(+1.33)Healthcare
GoAI Score
Sign in to unlock
Valuation
50Fair Value
Sentiment
100Bullish
Risk
77Low Risk
Momentum
100Positive
Institutional-Grade Intelligence
🏆PRO
Actionable Intelligence
AI-driven stance, execution logic & risk thresholds
Catalyst Roadmap
Event timeline with expected impact & market context
Deep Insights
Fact-checked analysis & score logic breakdown
Financial Statements
Margin Trends
No margin data
Valuation Snapshot
P/E Ratio
-13.1
Price vs earnings
EV/EBITDA
-12.5
Enterprise value
FCF Yield
-6.1%
Cash generation
Earnings Yield
-7.7%
Inverse of P/E
Capital Efficiency
-47
GoAI Quality ScorePoor
ROEReturn on Equity
-46.3%Weak
ROAReturn on Assets
-42.4%Weak
ROICReturn on Invested Capital
-50.1%Weak
Financial Health
Current RatioHealthy
14.67
Short-term solvency (>1.5)
Net Debt / EBITDAManageable
0.60x
Debt repayment capacity (<3x)
Income QualityFair
0.79
Cash backs earnings (>1)
Revenue & Profitability
No revenue data
Income Statement
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | -$546.00K | N/A | N/A | N/A | N/A |
| Gross Margin | N/A | N/A | N/A | N/A | N/A |
| Operating Income | -$132.76M | -$104.18M | -$79.94M | -$58.93M | -$26.29M |
| Net Income | -$119.95M | -$86.48M | -$69.13M | -$55.33M | -$26.29M |
| Net Margin | N/A | N/A | N/A | N/A | N/A |
| EPS | -$2.01 | -$1.51 | -$1.62 | -$1.23 | -$0.63 |
Average Price Target
$49.80▲ 25.7% Upside
Past 12 Months
12 Month Forecast
Based on 50 Wall Street analysts offering 12 month price targets for Tyra Biosciences, Inc., the average price target is $49.80, with a high forecast of $59.00 and a low forecast of $42.00. The average price target represents a 25.7% increase from the current price of $39.61.
Highest
$59.00
Average
$49.80
Lowest
$42.00
Rating Distribution
Strong Buy
0
0%
Buy
7
100%
Hold
0
0%
Sell
0
0%
Strong Sell
0
0%
Recent Analyst Ratings
FirmActionRatingDate
Piper Sandler● Maintain
Overweight
2026-03-20HC Wainwright & Co.● Maintain
Buy
2026-02-17Wedbush● Maintain
Outperform
2026-02-13Oppenheimer● Maintain
Outperform
2026-02-03Jefferies● Maintain
Buy
2026-02-03Piper Sandler● Maintain
Overweight
2026-01-23Wedbush● Maintain
Outperform
2025-12-16HC Wainwright & Co.● Maintain
Buy
2025-08-22HC Wainwright & Co.● Maintain
Buy
2025-07-01HC Wainwright & Co.● Maintain
Buy
2025-03-31Earnings History & Surprises
BEAT RATE
50%
Last 18 quarters
AVG SURPRISE
-9.3%
EPS vs Estimate
BEATS / MISSES
9/8
1 met exactly
LATEST EPS
$-0.57
Q1 '26
QUARTERLY EPS TREND
Estimated
Beat
Miss
QUARTERLY DETAIL
Q1 '26
-5.6%
$-0.57 vs $-0.54
Q4 '25
$-0.50 vs $-0.50
Q3 '25
+11.3%
$-0.47 vs $-0.53
Q2 '25
+4.1%
$-0.47 vs $-0.49
Q1 '25
+10.4%
$-0.43 vs $-0.48
Q4 '24
-2.5%
$-0.41 vs $-0.40
Q3 '24
+22.0%
$-0.32 vs $-0.41
Q2 '24
+23.9%
$-0.35 vs $-0.46
Q1 '24
-10.4%
$-0.53 vs $-0.48
Q4 '23
-40.0%
$-0.49 vs $-0.35
Q3 '23
+8.8%
$-0.31 vs $-0.34
Q2 '23
+24.3%
$-0.28 vs $-0.37
No investor questions available.
Latest News
No news available